Free Trial
NASDAQ:APRE

Aprea Therapeutics Q1 2024 Earnings Report

Aprea Therapeutics logo
$1.85 +0.04 (+2.20%)
Closing price 05/2/2025 03:58 PM Eastern
Extended Trading
$1.82 -0.03 (-1.62%)
As of 05/2/2025 05:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aprea Therapeutics EPS Results

Actual EPS
-$0.67
Consensus EPS
-$0.78
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Aprea Therapeutics Revenue Results

Actual Revenue
$0.38 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aprea Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Aprea Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Aprea Therapeutics Earnings Headlines

Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
See More Aprea Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email.

About Aprea Therapeutics

Aprea Therapeutics (NASDAQ:APRE), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

View Aprea Therapeutics Profile

More Earnings Resources from MarketBeat